Eliglustat is a first-line oral therapy for adults with Gaucher disease type 1 (GD1) and poor, intermediate or extensive CYP2D6-metabolizer phenotypes (>90% of patients). We report the final results of a Phase 2 trial and extension (NCT00358150) in previously untreated adult GD1 patients who had splenomegaly with thrombocytopenia and/or anemia and received 50 or 100 mg eliglustat tartrate (equivalent to 42 or 84 mg eliglustat) twice daily for 8 years. In total, 19 of 26 patients completed the trial. After 8 years of eliglustat, mean spleen and liver volumes decreased by 69% and 34%, respectively. Mean hemoglobin concentration and platelet count increased by 2.2 g/dL and 113%, respectively. All patients met at least 3 of 4 therapeutic goals established for patients on long-term enzyme replacement therapy. Mean final values for patients with severe splenomegaly (n = 6), moderate-to-severe anemia (n = 6), or severe thrombocytopenia (n = 8) were similar to patients with milder disease at baseline and within long-term therapeutic goal thresholds. Biomarker median percent changes from baseline were -91% for chitotriosidase, -87% for CCL18, -92% for glucosylsphingosine, and -80% for plasma glucosylceramide. Mean lumbar spine T-score increased by 0.96, moving from the osteopenic to the normal range. Mean quality-of-life scores, mostly below normal at baseline, moved into ranges seen in healthy adults. Eliglustat was well-tolerated; 98% of adverse events were mild or moderate and 94% were considered unrelated to treatment. Clinically meaningful improvements in all parameters continued or were maintained over 8 years, with the largest margins of improvement seen in the most severely affected patients.
| INTRODUCTION
Eliglustat (Cerdelga, Sanofi Genzyme) is an oral substrate reduction therapy approved in many countries worldwide, including the United States, Europe, and Japan, as a first-line therapy for adults with Gaucher disease type 1 (GD1) who have poor, intermediate, or extensive CYP2D6-metabolizer phenotypes (>90% of patients 1, 2 ). In Gaucher disease, inherited mutations in the acid β-glucosidase gene (OMIM 606463) result in deficient activity of the enzyme acid β-glucosidase (glucocerebrosidase) and pathogenic accumulation of its substrates, primarily glucosylceramide, in the spleen, liver, bone marrow, and occasionally the lungs. 3, 4 If untreated, substrate accumulation leads to hepatosplenomegaly, thrombocytopenia, anemia, skeletal disease, chronic bone pain, and growth failure (in children). 3 Eliglustat works by partially inhibiting glucosylceramide synthase to reduce synthesis of its major substrate, glucosylceramide, thereby restoring balance between substrate production and degradation.
The safety, efficacy, and tolerability of eliglustat therapy have been demonstrated in Phase 3 trials of previously untreated GD1 patients, as well as patients previously treated with enzyme replacement therapy (ERT) infusions, the historical standard of care. In the ENGAGE randomized, double-blind, placebo-controlled trial, eliglustat therapy improved hematologic, visceral, and skeletal disease parameters relative to placebo in treatment-naïve patients after 9 months, 5 and these improvements continued with up to 4.5 years of eliglustat therapy in the open-label trial extension. 6, 7 In the ENCORE trial of GD1 patients whose disease had been stable after a mean of 10 years on ERT, eliglustat was noninferior to imiglucerase ERT, 8 and the majority of patients maintained stable hematologic, visceral, and skeletal disease parameters for up to 4 years of eliglustat therapy. 9 As Gaucher disease requires lifelong therapy, long-term safety and efficacy of therapies are of paramount importance. We report the final 8-year outcomes of previously untreated adults with GD1 who completed the open-label, Phase 2 trial of eliglustat (NCT00358150, Sanofi Genzyme). These data represent the longest eliglustat therapy experience to date. They build on the 1-year outcomes, in which the primary endpoint of improvement in at least 2 of the 3 main efficacy parameters (spleen volume, hemoglobin level, and platelet count) was met, 10 as well as the 2-and 4-year data showing sustained improvements in hematologic parameters, organ volumes, disease-related biomarkers, and measures of bone health.
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| METHODS
The full methodology, inclusion and exclusion criteria, and 1-year primary endpoint analysis of this Phase 2 trial were published previously. 10 to adverse events, 1 of which was considered related to treatment; 3 due to pregnancy (2 during the first year, 1 after completion of the primary analysis period), and 1 for administrative reasons (patient was not able to continue in the trial under an amended protocol since the study site had not yet approved the amendment extending the trial beyond 2 years). As shown in Table 1 , baseline demographic and clinical characteristics were similar for the 26 patients who entered the trial and the 19 patients who completed 8 years of eliglustat therapy.
All but one patient had an extensive CYP2D6 metabolizer phenotype;
the remaining patient (a trial completer) had a poor metabolizer phenotype.
| Long-term efficacy
Improvements in spleen volume, liver volume, hemoglobin concentration, and platelet count, from baseline to 1 and 2 years of treatment continued or were maintained during 8 years of eliglustat therapy.
Mean and individual patient values for each parameter are shown in (from 50 to 128 × 10 9 /L) for patients with severe baseline 
Glucosylsphingosine (ng/mL) Abbreviations: DS3, Disease Severity Scoring System; MN, multiples of normal.
Unless otherwise noted, continuous characteristics are presented as mean values AE standard deviations (minimum, maximum) or median (minimum, maximum) and categorical characteristics as n (%). a Exceptions were granted for some patients with baseline platelet counts and spleen volumes outside the range established for inclusion criteria. b Excludes 2 patients with absent chitotriosidase (CHIT) activity due to a homozygous null mutation in the CHIT1 gene. c Normal ranges: chitotriosidase: <15-181 nmol/h/mL, chemokine ligand 18: 17-246 ng/mL, glucosylceramide: <2.0-6.6 μg/mL, glucosylsphingosine: <5 ng/mL. thrombocytopenia (n = 8) and by 75% (from 83 to 140 × 10 9 /L) for patients with absent, mild, or moderate baseline thrombocytopenia (n = 11).
As shown in Figure 3A , mean lumbar spine T-scores increased 
| Long-term biomarker response
The primary storage lipids (glucosylceramide and glucosylsphingosine) and established biomarkers (chitotriosidase and CCL18) of Gaucher disease were highly elevated at baseline. The marked reductions observed at 1 year continued or were maintained through 8 years of eliglustat therapy (Figure 4 ). After 8 years, median percent changes from baseline were -91% for chitotriosidase, -87% for CCL18, -92%
for glucosylsphingosine, and -80% for plasma glucosylceramide. The median plasma glucosylceramide level normalized within 6 months of starting eliglustat therapy and remained in the low-normal range for the duration of the trial.
| Long-term safety
This long-term trial represents a total of 169 patient-years of eliglustat exposure. In total, 98% of adverse events were mild or moderate and 94% were considered unrelated to eliglustat. Adverse events are summarized in Supporting Information she had stopped eliglustat therapy and had withdrawn from the trial at the end of the 1-year primary analysis due to pregnancy. The death was considered by the investigator to be unrelated to eliglustat. In total 5 patients reported 8 serious adverse events, including one that was considered by the investigator to be possibly related to eliglustat (a short run of asymptomatic nonsustained ventricular tachycardia
[NSVT]) and assessed as serious due to prolonged hospital stay on day 1 for a protocol-mandated 36-h cardiac telemetry for safety monitoring (from 12 h before through 24 h after the first dose), which was uneventful. 10 The 7 unrelated serious adverse events in the other 4 patients were as follows: ovarian cyst ruptured (severe); abortion spontaneous (severe) and 2 events of radiation exposure during pregnancy (mild) in the same patient; radiation exposure during pregnancy (moderate); and inguinal hernia (severe) and cholecystitis (severe) in the same patient. As reported previously, 10 3 patients withdrew from the trial due to 4 adverse events: 1 patient after 1 year for a moderate event of osteonecrosis retrospectively identified as present at baseline (considered unrelated to treatment) and 2 patients after day 1 for 3 events of asymptomatic NSVT detected during protocol-mandated 36-h ECG monitoring on day 1, 1 of which (also noted above) was considered possibly related to eliglustat by the investigator. In both patients, plasma eliglustat levels were undetectable at the time of the event.
Overall 5, patients reported 6 adverse events that were severe.
All were considered unrelated to eliglustat: ovarian cyst ruptured The therapeutic goal thresholds used for comparison in this study 18 have been the mainstay of assessing treatment effects in
Gaucher disease for more than a decade. These thresholds, which were developed based on real-world clinical outcomes data from the International Collaborative Gaucher Group Gaucher Registry, are aimed primarily at alleviating florid disease manifestations of anemia, thrombocytopenia, hepatosplenomegaly, skeletal pathology, and impaired growth (in children). Recently, a consensus panel of experts, with input from patients, developed a revised set of management guidelines that expands upon these parameters to include improvement in patient-reported outcomes, such as quality of life, fatigue and
Percent change from baseline in disease-related biomarkers during 8 years of eliglustat therapy. Percent reductions are based on patients who had data at both baseline and each timepoint. Baseline and year 8 values are based on patients who had data at both timepoints. *Chitotriosidase analysis excludes 2 patients with absent chitotriosidase (CHIT) activity due to homozygous null mutation in the CHIT1 gene.
social participation, as well as refractory elements of Gaucher disease, complications, and co-morbidities. 20 The thresholds for improvement in hemoglobin and hepatosplenomegaly remain essentially unchanged; whereas the platelet goal for nonsplenectomized patients was lowered from ≥120 × 10 9 /L (achieved by 63% of patients in our study) to ≥100 × 10 9 /L (achieved by 74% of patients in our study). In addition, 17 of 19 patients (89%) achieved platelet counts >80 × 10 9 /L, which is considered sufficient to prevent surgical, obstetric, and spontaneous bleeding. Persistent thrombocytopenia in some nonsplenectomized patients with severe baseline thrombocytopenia has been reported after 4, 5, or even 10 years of ERT, but the etiology remains unclear. 19, 21, 22 In our earlier analysis of 4-year platelet data from this trial, mean platelet counts did not correlate significantly with severity of thrombocytopenia, splenomegaly, or splenic filling defects at baseline; however, they did correlate with mean trough plasma concentrations of eliglustat. 13 The increase in mean and individual lumbar spine and femur Tscores during the first 3-4 years of eliglustat therapy is in keeping with the therapeutic goals developed for GD1 patients on ERT, which call for increasing bone density within 3-5 years of starting treatment. The long-term safety data from this trial extend the safety and tolerability profile of eliglustat reported among treatment-naïve patients during 1.5 years in the Phase 3 ENGAGE trial, 7 ERT switch patients during 4 years in the Phase 3 ENCORE trial, 9 and mostly ERT switch patients in the EDGE trial comparing once-vs twice-daily dosing of eliglustat. 24 These 4 trials represent a total of 393 eliglustattreated patients and 1400.3 patient-years of eliglustat exposure, with a mean duration of 3.6 years on eliglustat. 25 Nineteen of the 20 patients who entered the Phase 2 trial extension after the 1-year primary analysis completed the trial, with just one withdrawal at 2 years for administrative reasons.
This 8-year analysis provides new insights into long-term biomarker responses to eliglustat. The established Gaucher disease biomarkers, chitotriosidase and CCL18, both of which were highly elevated at baseline, were reduced by >85%. As seen in other trials of eliglustat, levels of the primary substrate glucosylceramide normalized within several months and remained in the low-normal range for the duration of the trial. Levels of the substrate glucosylsphingosine were reduced by 92%. This minor substrate of acid β-glucosidase is increasingly recognized as a highly specific and sensitive biomarker of
Gaucher disease with direct involvement in disease pathogenesis. [26] [27] [28] [29] These findings suggest that eliglustat therapy may reverse the pathological glycosphingolipid accumulation in Gaucher disease. 8 It should be noted that the study findings reflect outcomes for patients with intact spleens and relatively mild skeletal involvement at treatment initiation.
The study was initiated before widespread use of the bone marrow burden score and, therefore, does not include this important assessment of skeletal disease involvement.
In summary, clinically meaningful improvements in hematologic, visceral, bone, and biomarker parameters were achieved in previously untreated patients with GD1 as early as the first year of treatment with eliglustat. 10 These improvements continued or were maintained over the course of 8 years of eliglustat therapy. Quality-of-life measures also showed clinically significant improvements after 8 years of eliglustat. Eliglustat was generally safe and well tolerated with only 1 withdrawal due to an adverse event considered possibly related to eliglustat. and Regina Tayag (Prometrika LLC) for biostatistical analyses.
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